Independent studies of the corpulent SHR showed that blockade of angiotensin II type 1 receptor [46] or mineralocorticoid receptor [25, 47], inhibition of angiotensin converting enzyme [48], or antioxidant therapy [49, 50] all significantly decreased blood pressure indicating that angiotensin II and its downstream effects mediated the hypertension. The gene discussed is AGTR1; the disease is hypertensive disorder.